Sender:	Spivey Richard WALLACE/OU=CRANMAIL/CN=RECIPIENTS/CN=EXCHANGE/CN=RSPIVEY>
Sent:	Monday, February 06, 2006 1:38:53 PM
Recipient:	D'Addio Alex <adaddio@medpointepharma.com>;Fuge Dennis <dfuge@medpointepharma.com></dfuge@medpointepharma.com></adaddio@medpointepharma.com>
Subject:	RE: Pfeiffer Bi Dose Nasal Spray System

Dennis,

Could you mention this to Paul (or I can)? He is of the impression this is a dual chamber device. Please advise.

Thanks,

Rich

-----Original Message-----From: D'Addio Alex Sent: Saturday, February 04, 2006 3:36 PM To: Spivey Richard; Fuge Dennis Subject: RE: Pfeiffer Bi Dose Nasal Spray System

Rich,

You are correct. The Valois Bidose is a single-use device intended to deliver two sprays - one for each nostril - of a single formulation. It is a specialty device developed for use in applications such as mucosal vaccinations.

Dennis,

I am available after the Valois meeting to discuss development of a potential combo product.

Alex

-----Original Message-----From: Spivey Richard Sent: Friday, February 03, 2006 8:35 AM To: Fuge Dennis Cc: D'Addio Alex Subject: RE: Pfeiffer Bi Dose Nasal Spray System

Good.

Thanks,

Rich

-----Original Message-----From: Fuge Dennis Sent: Fri Feb 03 08:12:48 2006 To: Spivey Richard Cc: D'Addio Alex Subject: RE: Pfeiffer Bi Dose Nasal Spray System

Rich, Valois are coming in on Monday to talk to us about the Bi Dose. Dennis

From: Spivey Richard Sent: Thursday, February 02, 2006 10:41 PM





MEDA\_APTX03470974 CIP2121 Argentum Pharmaceuticals LLC v. Cipla Ltd. IPR2017-00807 To: Fuge Dennis Cc: D'Addio Alex Subject: RE: Pfeiffer Bi Dose Nasal Spray System

You should discuss with Alex. Everyone is fully committed at this point. We had always wanted to wait until after the proff of concept results (April) before spending much resource on this. It may be possible to do some rudimentary testing, but this should be discussed with Alex.

Also, as we discussed, I have seen nothing that would indicate that the bi-dose is anything other than two doses, not a dual chamber. Can't we quickly find that out?

Rich

From: Fuge Dennis Sent: Monday, January 30, 2006 11:58 AM To: Spivey Richard Subject: RE: Pfeiffer Bi Dose Nasal Spray System

Rich,

As discussed there are likely to be a number of easier formulation options for the steroid compo product than going the dual device/chamber route. Can we turn Gul loose to do work on whether one of the existing steroid suspensions or solutions would accept the addition of Azelastine and be stable? I am not looking at a full development effort, just something small to confirm conceptually whether we are going to face major formulation issues or whether an existing formulation could be the starting point.

In the meantime, I will explore device options with Valois. Best regards, Dennis

From: Edick Paul Sent: Saturday, January 28, 2006 10:57 AM To: Fuge Dennis Cc: Fishman Corey; Spivey Richard; Coniglio Tony Subject: RE: Pfeiffer Bi Dose Nasal Spray System

Dennis,

We should put this on the front burner and pursue as exclusive for use in Rhinitis applications ASAP.

Paul

From: Fuge Dennis Sent: Friday, January 27, 2006 10:54 AM To: sarah.malka@valois.com Cc: Spivey Richard; Coniglio Tony; Edick Paul; Fishman Corey Subject: Pfeiffer Bi Dose Nasal Spray System

Sarah,

At our meeting on February 6th could you give your brief perspective on the Pfeiffer's Bi Dose Nasal System and the types of products this device is used for, just so that we can assess whether this could be something worth exploring in the future? Could you also explain to us how the coordination of activities in the AptarGroup are actually working. Are there separate sales representatives? Would a supply agreement cover the total AptarGroup or just the Valois division?

Thanks. Best regards, Dennis

MEDA\_APTX03470975